Mouse anti-Mouse IL-33 Monoclonal Antibody | anti-IL-33 antibody

Mouse Anti-IL-33 (Interleukin-33, IL-1F11, NF-HEV)

Cat. Num. AAA6120617

• Reactivity: Mouse
• Applications: ELISA
• Purity: Purified by Protein A affinity chromatography.
• Synonyms: IL-33; Monoclonal Antibody; Mouse Anti-IL-33 (Interleukin-33; IL-1F11; NF-HEV); anti-IL-33 antibody

• Host: Mouse
• Reactivity: Mouse
• Clonality: Monoclonal
• Isotype: IgG2b
• Clone Number: Bondy-1-1
• Specificity: Recognizes mouse IL-33.
• Purity/Purification: Purified by Protein A affinity chromatography.
• Form/Format: Supplied as a liquid in PBS, 10% glycerol. No preservative added.

• Applicable Applications for anti-IL-33 antibody: ELISA (EIA)
• Endotoxin: <0.01EU/ug purified protein (LAL test; Lonza)
• Immunogen: Recombinant protein corresponding to mouse IL-33 expressed in HEK 293 cell culture supernatant.
• Preparation and Storage: May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Structure

(Structure of the recombinant antibody IL-33 (mouse), mAb (rec.) (blocking) (preservative free). The single chain variable human fragment (ScFv) selected by antibody phage display technology and specific to the antigen of interest is fused to a mouse IgG2b Fc region.)

ELISA (EIA)

(Binding of IL-33 (mouse) to ST2/IL-1RAcp is inhibited by IL-33 (mouse), mAb (rec.) (blocking) (preservative free).|Methods: IL-33 (mouse) was coated on an ELISA plate at 1ug/ml. IL-33 (mouse), mAb (rec.) (blocking) (preservative free) or an unrelated mAb (recombinant) (Control) were added (starting at 40u/ml with a twofold serial dilution) together with 100ul of supernatant of cells containing ST2 (human): Fc/IL-1RAcp (human): Fc. After incubation for 1h at RT, the binding was detected using an anti-Fc human antibody (HRP).)

Related Product Information for anti-IL-33 antibody

Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. Anti-IL-33, mAb (recombinant) (blocking) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.

References

1. Regulation of de novo adipocyte differentiation through crosstalk between adipocytes and pre-adipocytes: T.D. Challa, et al.; Diabetes 64, 4075 (2015).